Resource Logo
NLM AIDSLINE

Role of caspases 1 and 3 and Bcl-2-related molecules in endothelial cell apoptosis associated with thrombotic microangiopathies.




 

Am J Hematol. 1998 Dec;59(4):279-87. Unique Identifier : AIDSLINE

We have defined an in vitro model for the study of microvascular endothelial cell (EC) apoptosis mediated by plasma from patients with various forms of thrombotic thrombocytopenic purpura (TTP) and hemolytic-uremic syndrome (HUS). This system reproduces a variety of histopathologic and ultrastructural features of tissue EC involved in TTP/sporadic HUS, suggesting that apoptotic EC injury is a primary pathophysiologic event in the thrombotic microangiopathies. We now document the ability of tetrapeptide-based inhibitors of interleukin 1beta-converting enzyme (ICE)-like caspase 1 and cysteine protease protein (CPP)-32-like caspase 3, two members of a novel class of cysteine proteases involved in final pathways to apoptosis, to block TTP/sporadic HUS plasma-mediated apoptosis. Overexpression of Bcl-X(L) via gene transfer suppressed this apoptosis by 70%. Transduction of EC with the Bcl-2 homolog A1 had a more limited protective effect. These findings support a role for apoptosis-linked cysteine proteases in the pathophysiology of TTP and sporadic HUS, and raise the possibility that specific apoptosis inhibitors may have a role in the experimental therapeutics of these syndromes.

JOURNAL ARTICLE Apoptosis/*PHYSIOLOGY Autoimmune Diseases/*METABOLISM/PATHOLOGY Caspase 1/ANTAGONISTS & INHIB/*PHYSIOLOGY Caspases/ANTAGONISTS & INHIB/*PHYSIOLOGY Cells, Cultured Endothelium, Vascular/METABOLISM/*PATHOLOGY Hemolytic-Uremic Syndrome/*METABOLISM/PATHOLOGY Human HIV Infections/METABOLISM/PATHOLOGY Protease Inhibitors/PHARMACOLOGY Proto-Oncogene Proteins c-bcl-2/GENETICS/*PHYSIOLOGY Purpura, Thrombocytopenic, Idiopathic/*METABOLISM/PATHOLOGY Recombinant Fusion Proteins/PHYSIOLOGY Support, U.S. Gov't, P.H.S.



 




Information in this article was accurate in February 28, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.